Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health | ||||||||||||||||||||||||||
By: GlobeNewswire - 20 Mar 2024 | Back to overview list |
|||||||||||||||||||||||||
WINNIPEG, Manitoba, March 20, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity period on the offer for its interest in STEM Animal Health that it announced on December 20, 2023, from March 19, 2024 until March 31, 2024. Kane further announces that subsequent to the US $625,000 deposit that it received at the time of the offer, Kane has received additional deposits totaling US $900,000 which will be applied towards the sale price of Kane’s interest in STEM. About Kane Biotech Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (67 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
Caution Regarding Forward-Looking Information |
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Copyright 2024 GlobeNewswire | Back to overview list |